Costa Rica Pharmaceuticals and Healthcare Report Q2 2016 95893 Now Available at LifeScienceIndustryResearch.com

Costa Rica Pharmaceuticals and Healthcare Report Q2 2016

38 pages report Published in Mar 2016

Pharmaceuticals

Publisher: Business Monitor International

Report Description
Table of Content
Related Reports

BMI View: Costa Rica’s increasing demand for healthcare and improving regulatory regime will support
its long-term pharmaceutical market growth. The relatively stable economic and political climate in Costa
Rica will continue to provide a business friendly environment for pharmaceutical companies to invest in the
local market.
Headline Expenditure Projections
Pharmaceuticals: CRC446.9bn (USD813mn) in 2015 to CRC469.5bn (USD861mn) in 2016; +5.0% in
local currency terms and 6.0% in US dollar terms. Forecast in has stayed the same as in Q116.
Healthcare: CRC2,779.5bn (USD5.1bn) in 2015 to CRC2,968.9bn (USD5.4bn) in 2016; +6.8% in local
currency terms and 7.8% in US dollar terms. Forecast in local currency has been revised upwards from
Q116.

Table of Contents

BMI Industry View 5
Table: Headline Pharmaceuticals & Healthcare Forecasts (Costa Rica 2014-2020) 5
SWOT 7
Industry Forecast 8
Pharmaceutical Market Forecast 8
Table: Pharmaceutical Sales, Historical Data And Forecasts (Costa Rica 2012-2020) 9
Healthcare Market Forecast 10
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Costa Rica 2012-2020) 11
Industry Risk Reward Index 12
Americas Risk/Reward Index 12
Industry Risk Reward Index 18
Regulatory Review 20
Intellectual Property Issues 20
Market Overview 22
Healthcare Sector 22
Epidemiology 24
Competitive Landscape 26
Pharmaceutical Distribution & Retail Sector 26
Demographic Forecast 27
Demographic Outlook 27
Table: Population Headline Indicators (Costa Rica 1990-2025) 28
Table: Key Population Ratios (Costa Rica 1990-2025) 28
Table: Urban/Rural Population & Life Expectancy (Costa Rica 1990-2025) 29
Table: Population By Age Group (Costa Rica 1990-2025) 29
Table: Population By Age Group % (Costa Rica 1990-2025) 30
Glossary 32
Methodology 34
Pharmaceutical Expenditure Forecast Model 34
Healthcare Expenditure Forecast Model 34
Notes On Methodology 35
Risk/Reward Index Methodology 36
Index Overview 37
Table: Pharmaceutical Risk/Reward Index Indicators 37
Indicator Weightings 38

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Costa Rica 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Costa Rica 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Costa Rica 2012-2020)
Table: Population Headline Indicators (Costa Rica 1990-2025)
Table: Key Population Ratios (Costa Rica 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Costa Rica 1990-2025)
Table: Population By Age Group (Costa Rica 1990-2025)
Table: Population By Age Group % (Costa Rica 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators

Related Reports

Croatia Pharmaceuticals and Healthcare Report Q2 2016BMI View: Continued political instability coupled with a bleak economic outlook will continue to repress the pharmaceutical and healthcare sectors in Croatia. Necessary austerity measures will impose further barriers towards growth and reduce the use of high-value patented drugs, highlighting minimal revenue earning opportunities for multinational pharmaceutical firms. Headline Expenditure Projections ? Pharmaceuticals: HRK6.73bn (USD961mn) in 2015 to HRK6.76bn (USD931mn) in 2016; […]
Egypt Pharmaceuticals and Healthcare Report Q4 2015BMI View: Egypt's pharmaceutical market presents one of the most attractive investment destinations for multinational drugmakers in the MENA region. A large market size and population, coupled with an improved political and economic outlook, support our positive outlook for Egypt. Headline Expenditure Projections ? Pharmaceuticals: EGP29.50bn (USD4.17bn) in 2014 to EGP33.08bn (USD4.24bn) in 2015; +12.1% in local currency terms and 1.7% in US dollar terms. Forecast upgraded from […]
Jordan Pharmaceuticals and Healthcare Report Q1 2016BMI View: Jordan offers an attractive pharmaceutical market for multinational drugmakers, although its potential will remain impeded by the ongoing political and economic instability in neighbouring Syria - which is having a detrimental impact on Jordan's healthcare sector. Headline Expenditure Projections ? Pharmaceuticals: JOD643mn (USD905mn) in 2014 to JOD683mn (USD962mn) in 2015; +6.3% in local currency terms and US dollar terms. Forecast unchanged from Q415. ? Healthcare: […]
Philippines Pharmaceuticals and Healthcare Report Q3 2014BMI View: Medicine pricing controls will continue to limit the growth potential of the Philippine pharmaceutical market. However, over the longer term progressive implementation of universal healthcare coverage, coupled with the country's relatively strong economic growth and political stability, will boost pharmaceutical consumption. Headline Expenditure Projections ? Pharmaceuticals: PHP138.45bn (USD3.20bn) in 2013, rising to PHP143.55bn (USD3.26bn) in 2014; +3.7% in local currency […]
Czech Republic Pharmaceuticals and Healthcare Report Q2 2016BMI View: The Czech Republic will continue to be one of the most attractive markets in the CEE region for pharmaceutical and healthcare investment. A strong economic outlook will be the driving factor behind growth, with plans to further increase access to healthcare; pharmaceutical sales are expected to increase over the coming years. Headline Expenditure Projections ? Pharmaceuticals: CZK78.83bn (USD3.01bn) in 2015 to CZK81.10bn (USD3.27bn) in 2016; +2.9% in local currency terms […]